Form 4: ImmunityBio CFO David Sachs Awarded Stock Options and Restricted Stock Units

David C. Sachs, CFO of ImmunityBio, Inc., received stock options and restricted stock units on February 10, 2025, according to a Form 4 filing.

Summary

• A Form 4 filing reveals that David C. Sachs, the Chief Financial Officer of ImmunityBio, Inc. (IBRX), was granted stock options and restricted stock units (RSUs) on February 10, 2025.
• Sachs received 246,710 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of ImmunityBio common stock.
• These RSUs will vest in three annual installments starting on the first anniversary of the vesting commencement date (February 10, 2025), with 33.33% vesting on the first and second anniversaries and 33.34% vesting on the third anniversary.
• Sachs also received options to purchase 843,750 shares of ImmunityBio common stock at an exercise price of $3.39.
• These options also vest in three annual installments, mirroring the RSU vesting schedule, contingent upon Sachs' continued service.
• The options expire on February 10, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of management interests. It's a neutral-positive signal.

Positives

• The granting of stock options and RSUs to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Stock option and RSU grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. The size of the grant and the vesting schedule are typical for a company of ImmunityBio's size and stage.

Comparison to Industry Standards

• Stock option grants to CFOs in biotech companies are common, with the size of the grant typically tied to the company's market capitalization and the CFO's experience.
• Vesting schedules of three to four years are standard in the industry to ensure long-term commitment.
• Comparable companies like Sorrento Therapeutics or NantKwest (prior to its merger with ImmunityBio) have used similar equity-based compensation strategies.

Stakeholder Impact

• Shareholders may view the grant positively as it incentivizes the CFO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, ImmunityBio, IBRX, David Sachs, CFO, Stock Options, Restricted Stock Units, RSU, Vesting